查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999341

生技與製藥服務外包市場：2026-2032年全球市場預測（按服務類型、外包模式、公司規模、治療領域和服務供應商類型分類）

Biotechnology & Pharmaceutical Services Outsourcing Market by Service Type, Mode of Outsourcing, Company Size, Therapeutic Area, Service Provider Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生物技術、製藥服務和外包市場價值將達到 585.4 億美元，到 2026 年將成長至 618.6 億美元，到 2032 年將達到 874.5 億美元，複合年成長率為 5.89%。

主要市場統計數據
基準年 2025 585.4億美元
預計年份：2026年 618.6億美元
預測年份 2032 874.5億美元
複合年成長率 (%) 5.89%

探索塑造當今生物技術和製藥外包產業的策略基礎和關鍵促進因素。

生物技術和製藥服務外包產業正處於關鍵的轉折點，其驅動力來自治療方法的創新和日益成長的成本壓力。細胞和基因療法的快速發展，以及日益複雜的臨床和監管要求，正在推動對專業外部專家的需求不斷成長。同時，各組織機構也面臨持續的審查，需要在縮短產品上市時間、維持品質標準和最佳化資本配置方面承受巨大壓力。

檢驗醫藥外包產業服務交付方式的重大技術進步和營運變革。

近年來，隨著先進的分析工具和自動化平台重新定義了營運預期，外包格局發生了翻天覆地的變化。人工智慧驅動的試驗設計和基於機器學習的數據分析如今已成為決策支援系統的基礎，加速了化合物篩選和病患招募策略的發展。同時，基於雲端的協作入口網站已成為即時資料交換的關鍵，有助於提高地理位置分散的團隊之間的透明度和合規性。

本研究探討了 2025 年美國對生物技術和製藥外包徵收關稅的廣泛經濟和貿易政策影響。

美國將於2025年實施新的關稅體系，將對從海外合作夥伴採購實驗室耗材、活性藥物成分和設備帶來複雜的成本和合規性挑戰。依賴全球供應鏈的製造商和臨床研究機構正面臨關稅上漲，被迫重新評估其供應商組合和物流網路。為了應對這些不利因素，許多相關人員正在探索近岸外包方案，並尋求與國內合約研發生產力機構（CDMO）建立合作關係，以降低關稅風險。

細分市場洞察揭示了服務類型、外包模式、公司規模、治療區域和提供者類型如何影響產業成長。

對市場區隔的深入檢驗揭示了各類服務需求的細微差別，涵蓋了從臨床試驗的各個階段到複雜監管策略支援的各個方面。臨床試驗服務（涵蓋I期至IV期）持續受到廣泛關注，申辦方尋求端到端的患者招募和臨床實驗管理方面的專業知識；同時，諮詢服務（包括併購諮詢和市場進入策略）也日益被利用，以應對不斷變化的醫保報銷環境。

分析影響美洲、歐洲、中東和非洲以及亞太地區外包產業的區域特定因素、監管環境和創新能力。

區域趨勢揭示了影響外包策略的獨特創新生態系統和法規結構。在美洲，生物技術中心和頂級臨床試驗機構的集中推動了對全方位服務解決方案的需求，而積極的貿易政策和獎勵則支持了國內製造業的擴張。不斷變化的報銷模式以及對以病人為中心的臨床試驗的日益重視，進一步加速了分散式臨床服務的提供。

對生物製藥行業領先的合約研究、生產和諮詢公司的競爭策略、合作夥伴關係和發展路徑進行評估。

領先的合約研究組織 (CRO) 正透過策略聯盟、拓展營運基地和端到端平台整合來實現差異化競爭。多家主要企業正尋求與專業生技公司建立合資企業，共同開發細胞療法生產和進階分析等特色能力。這些夥伴關係增強了它們的服務組合，並加速了它們獲取最尖端科技的進程。

我們為領導企業提供切實可行的策略建議，以最佳化服務交付創新和業務永續營運。

產業領導企業應優先投資於能夠促進全球企劃團隊無縫協作並加速即時數據視覺化的數位化平台。實施先進的分析和人工智慧驅動的決策支援工具，不僅可以簡化臨床實驗設計和受試者招募流程，還能加強監管鍊和品質監控的風險管理。

詳細介紹了嚴格的多模態調查方法，該方法結合了與專家的初步訪談、全面的二手研究和資料三角驗證方法。

本研究採用綜合性的多模態方法，首先廣泛查閱同行評審文章、產業白皮書和監管文件，建構堅實的二手資料基礎。然後整合政府資料庫和專家產業報告的關鍵見解，以檢驗整體市場和政策趨勢。

對醫藥服務外包相關人員的關鍵趨勢、策略意義和未來前景進行全面分析。

在技​​術突破、貿易政策演變和客戶偏好變化的推動下，生物技術和製藥服務外包生態系統正在迅速成熟。策略合作、數位轉型和區域擴張正成為成長和韌性的關鍵驅動力。為了適應這些需求，企業必須在專業知識需求和整合服務模式所帶來的效率之間取得平衡。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生技、製藥服務與外包市場：依服務類型分類

  • 臨床試驗服務
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段
  • 諮詢服務
    • 併購諮詢
    • 市場准入和贖回諮詢
    • 投資組合管理
    • 策略諮詢
  • 製造服務
    • 原料藥（API）生產
    • 合約開發與生產組織 (CDMO) 服務
    • 灌裝和包裝服務
    • 配方開發
    • 包裝/展示
    • 規模擴大和技術轉移
  • 藥物安全監測服務
  • 臨床前服務
    • 動物實驗
    • 生物分析測試
    • DMPK 測試
    • 藥理學考試
    • 毒性測試
  • 品管服務
  • 醫藥服務
    • 與監管機構聯絡和代表
    • 申請文件準備
    • 標籤和包裝合規性
    • 藥物警戒和安全性監測
    • 監理策略與應用
  • 研究與開發服務
    • 檢測方法開發
    • 生物標記發現
    • 先導化合物的鑑定與最佳化
    • 目標驗證

第9章：按外包類型分類的生物技術、製藥服務和外包市場

  • 全方位外包
  • 功能服務供應商（FSP）模型
  • 戰術性/企劃為基礎外包

第10章：依公司規模分類的生物技術、製藥服務和外包市場

  • 主要企業
  • 中小企業

第11章：生技、製藥服務與外包市場：依治療領域分類

  • 循環系統
  • 皮膚科
  • 消化系統
  • 免疫學
  • 感染疾病
  • 代謝性疾病
  • 神經病學
  • 腫瘤學
  • 兒童
  • 罕見疾病
  • 呼吸系統

第12章：按服務供應商類型分類的生物技術、製藥服務和外包市場

  • 顧問公司
  • 合約研發生產組織（CDMO）
  • 契約製造組織（CMO）
  • 合約研究組織（CRO）
  • 資料管理和IT服務供應商
  • 醫藥監理相關企業

第13章：生技、製藥服務與外包市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：生技、製藥服務與外包市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生技、製藥服務與外包市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生技、製藥服務與外包市場

第17章：中國的生技、醫藥服務與外包市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AmerisourceBergen Corporation
  • Catalent, Inc.
  • CEVA Logistics AG
  • Charles River Laboratories, Inc.
  • Concept Heidelberg GmbH
  • Curia Global, Inc.
  • Dalton Pharma Services by Seikagaku Corporation
  • DHL International GmbH
  • Eurofins Scientific（Ireland）Limited
  • Evotec SE
  • GenScript Biotech Corporation
  • Icon PLC
  • IQVIA HOLDINGS, INC.
  • Laboratory Corporation of America Holdings
  • Lachman Consultant Services, Inc.
  • McKesson Corporation by Aurelius Group
  • Medpace Holdings, Inc.
  • Parexel International Corporation
  • Syneos Health, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-3A2E844FE146

The Biotechnology & Pharmaceutical Services Outsourcing Market was valued at USD 58.54 billion in 2025 and is projected to grow to USD 61.86 billion in 2026, with a CAGR of 5.89%, reaching USD 87.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 58.54 billion
Estimated Year [2026] USD 61.86 billion
Forecast Year [2032] USD 87.45 billion
CAGR (%) 5.89%

Discovering the Strategic Foundations and Critical Drivers Shaping the Biotechnology and Pharmaceutical Outsourcing Industry Today

The biotechnology and pharmaceutical services outsourcing sector stands at a pivotal juncture, driven by evolving therapeutic innovations and mounting cost pressures. Rapid advancements in cell and gene therapies, coupled with the increasing complexity of clinical and regulatory requirements, have expanded the demand for specialized external expertise. Meanwhile, organizations are under relentless scrutiny to accelerate time to market, maintain quality standards and optimize capital deployment.

Within this dynamic environment, outsourcing partners play an instrumental role in augmenting in-house capabilities and mitigating operational risks. An array of service models now spans from full-service contract research organizations to tactical project-based support, allowing companies to tailor collaborations according to strategic imperatives. In parallel, digital transformation initiatives are reshaping traditional workflows, driving deeper integration between sponsors and service providers.

As industry stakeholders adapt to these shifts, understanding the strategic foundations and key drivers becomes essential for informed decision making. This introduction sets the stage by outlining core market catalysts such as regulatory complexity, technological innovation and economic considerations. By contextualizing these forces, readers will gain clarity on the factors shaping service demand and partnership models, preparing them to navigate an increasingly competitive and interconnected outsourcing landscape.

Examining the Dramatic Technological Advancements and Operational Transformations Redefining Service Delivery in the Pharmaceutical Outsourcing Landscape

In recent years, the outsourcing landscape has undergone profound transformation as advanced analytical tools and automation platforms have redefined operational expectations. Artificial intelligence-powered trial designs and machine learning-driven data analytics now underpin decision support systems, accelerating compound selection and patient recruitment strategies. Concurrently, cloud-based collaboration portals have become integral for real-time data exchange, fostering enhanced transparency and compliance across geographically dispersed teams.

These technological breakthroughs coincided with a shift toward more hybridized service offerings. Traditional full-service models are increasingly complemented by specialized functional service provider arrangements, enabling clients to maintain direct oversight of critical study components while outsourcing noncore functions. As a result, service providers are expanding niche capabilities-such as advanced biomarker discovery or adaptive trial management-to differentiate their value proposition and forge deeper partnerships.

Moreover, sustainability considerations and social responsibility initiatives are influencing provider selection. Clients now prioritize partners with robust environmental, social and governance frameworks, viewing these commitments as indicators of operational resilience and ethical stewardship. As the industry evolves, service organizations that integrate cutting-edge technologies with flexible operating models and strong ESG practices will be best positioned to lead the next wave of outsourcing innovation.

Unpacking the Broad Economic and Trade Policy Effects of the United States Tariffs on Biotechnology and Pharma Outsourcing in 2025

The imposition of new tariff regimes by the United States in 2025 has introduced a complex layer of cost and compliance considerations for sourcing laboratory supplies, active pharmaceutical ingredients and equipment from overseas partners. Manufacturers and clinical research organizations reliant on global supply chains have encountered elevated duties, prompting a reassessment of supplier portfolios and logistics networks. To manage these headwinds, many stakeholders are exploring near-shoring options and forging partnerships with domestic contract development and manufacturing organizations to circumvent tariff exposures.

At the same time, increased duties on specialized reagents and analytical instruments have led to pricing pressures across preclinical and clinical development activities. Service providers are responding by negotiating volume discounts, implementing consolidated shipping strategies and adopting lean inventory practices. These adjustments have delivered near-term cost relief but also introduced complexity into demand forecasting and capacity planning.

Strategically, the tariff landscape has incentivized dual-sourcing frameworks to mitigate single-source vulnerabilities. By diversifying procurement channels and investing in regional manufacturing footprints, companies can better manage financial risks and maintain continuity. In this evolving trade policy environment, proactive supply chain optimization and collaborative vendor ecosystems are emerging as critical enablers for sustaining efficient outsourcing operations.

Uncovering Segmentation Insights That Illuminate How Service Types Outsourcing Models Company Sizes Therapeutic Areas and Provider Types Shape Industry Growth

A rigorous examination of market segmentation uncovers nuanced demand drivers across a spectrum of service types ranging from clinical trial phases to complex regulatory strategy support. Clinical trial services spanning phases I through IV continue to capture significant attention as sponsors seek end-to-end patient recruitment and site management expertise, while consulting services encompassing M&A advisory and market access strategy are increasingly leveraged to navigate changing reimbursement landscapes.

Within manufacturing, specialized contract development and manufacturing organizations offering formulation development and scale-up capabilities are gaining traction, especially for novel modalities. Preclinical suppliers delivering bioanalytical testing and toxicology assessments play a critical role in de-risking early-stage assets, while pharmacovigilance and quality management services ensure rigorous safety monitoring throughout the product lifecycle. Moreover, research and development firms focusing on assay development, biomarker discovery and target validation provide indispensable insights that refine lead optimization and accelerate translational research.

The mode of outsourcing further differentiates strategic alignment: full-service partnerships deliver integrated program management, whereas functional service provider models and project-based engagements offer targeted flexibility. Additionally, the interplay between large enterprises and small to medium-sized biotechnology firms shapes procurement preferences, with larger sponsors often favoring comprehensive end-to-end solutions while emerging companies selectively outsource high-value research tasks. Finally, therapeutic area specialization and provider type-ranging from contract research to data management and regulatory affairs firms-reflect diverse competency needs and drive differential growth trajectories across the industry.

Analyzing the Unique Regional Drivers Regulatory Landscapes and Innovation Capacities Shaping the Americas EMEA and AsiaPacific Outsourcing Sectors

Regional dynamics reveal distinct innovation ecosystems and regulatory frameworks that influence outsourcing strategies. In the Americas, a robust concentration of biotech hubs and top-tier clinical sites drives demand for full-service solutions, while proactive trade policies and incentives support domestic manufacturing expansion. Shifting reimbursement models and an emphasis on patient-centric trials further spur growth in decentralized clinical service offerings.

Across Europe, the Middle East and Africa, harmonized regulatory initiatives such as the EU Clinical Trials Regulation are fostering greater cross-border collaboration and standardization in safety reporting. This regulatory convergence, combined with established contract research infrastructure, has elevated the region's appeal for midstage and late-stage clinical programs. At the same time, emerging markets within the Middle East and Africa are attracting investments in site development and pharmacovigilance capabilities, underpinned by government-sponsored research partnerships.

In the AsiaPacific corridor, rapid capacity expansion in contract development and manufacturing is reshaping global supply chain architectures. Nations across the region are investing heavily in biotech clusters, incentivizing API production and advanced fill-finish platforms. The integration of digital health initiatives and supportive regulatory frameworks accelerates clinical trial innovation, making AsiaPacific an increasingly strategic destination for cost-efficient, high-quality outsourced services.

Evaluating the Competitive Approaches Partnerships and Growth Paths of Major Contract Research Manufacturing and Consulting Organizations Shaping Biopharma

Leading contract research organizations are differentiating through strategic alliances, geographic footprint expansion and end-to-end platform integrations. Several top players have pursued joint ventures with specialized biotech firms to co-develop niche capabilities in cell therapy manufacturing and advanced analytics. These partnerships enhance service portfolios and accelerate access to cutting-edge technologies.

Similarly, leading CDMOs are investing in modular facility designs that support agile production scale-up, addressing the growing demand for personalized medicine manufacturing. To strengthen downstream capabilities, some providers have acquired packaging and labeling specialists, thereby streamlining tech transfer processes and minimizing regulatory hurdles. Contract manufacturing organizations also continue to refine their quality and compliance frameworks to meet the stringent standards required for biologics and high-potency compounds.

Consulting firms and regulatory affairs specialists are forging closer collaborations with industry associations and regulatory agencies to influence policy dialogues and expedite dossier approvals. Data management and IT service providers, in turn, are embedding robust cybersecurity and AI-driven analytics into trial management systems to optimize data integrity and accelerate decision cycles. Collectively, these competitive strategies underscore the imperative for integrated service offerings and continuous innovation to maintain leadership positions in the biopharma outsourcing arena.

Providing Actionable Strategic Recommendations for Biopharma Outsourcing Leaders to Optimize Service Delivery Innovation and Operational Resilience

Industry leaders should prioritize investments in digital platforms that facilitate seamless collaboration across global project teams and accelerate real-time data visibility. Implementing advanced analytics and AI-driven decision support tools will not only streamline trial design and patient recruitment but also enhance risk management in chain-of-custody and quality oversight.

Furthermore, building resilient supply chains through diversified sourcing and near-shoring strategies can mitigate tariff-induced cost fluctuations and regulatory uncertainties. Organizations should cultivate strategic alliances with regional manufacturers and logistics partners to bolster capacity flexibility and accelerate response times during demand surges.

In parallel, fostering deep specialized expertise within niche therapeutic and technical domains can drive competitive differentiation. By aligning service offerings with emerging modalities such as cell and gene therapy, companies can capture higher-value contracts and strengthen long-term client relationships. Lastly, embedding robust environmental, social and governance principles into operational frameworks will not only address stakeholder expectations but also signal a commitment to sustainable and ethical practices, reinforcing brand integrity and stakeholder trust.

Detailing the Rigorous Multimodal Research Methodology Combining Primary Expert Interviews Comprehensive Secondary Research and Data Triangulation Approaches

This research employs a comprehensive multimodal approach beginning with an extensive review of peer-reviewed publications, industry white papers and regulatory filings to construct a solid secondary data foundation. Key insights from government databases and specialized trade reports were synthesized to validate overarching market trends and policy developments.

Primary research involved in-depth interviews with senior executives at leading service providers, global biopharma sponsors and regulatory experts to capture firsthand perspectives on operational challenges and emerging opportunities. Respondent feedback was systematically triangulated with quantitative and qualitative data points to ensure robust findings.

Data analysis combined thematic content evaluation with cross-functional benchmarking, enabling identification of service innovation patterns and competitive differentiation strategies. Finally, the integrated methodology was governed by strict data validation protocols, ensuring the reliability and reproducibility of insights while maintaining transparency of assumptions and limitations throughout the research lifecycle.

Concluding with Holistic Reflections Synthesizing Key Trends Strategic Implications and Future Perspectives for Pharmaceutical Service Outsourcing Stakeholders

The outsourcing ecosystem for biotechnology and pharmaceutical services is rapidly maturing, fueled by technological breakthroughs, evolving trade policies and shifting client preferences. Strategic collaborations, digital transformation and regional expansion have emerged as pivotal levers for growth and resilience. As companies adapt to these imperatives, they must balance the need for specialized expertise with the efficiencies offered by integrated service models.

Moreover, trade-driven cost pressures underscore the importance of supply chain diversification and near-shore manufacturing investments. Regulatory harmonization efforts across major markets continue to streamline clinical development pathways, yet demand for localized compliance expertise remains high. Segmentation insights reveal that no single operating model will suffice; rather, success hinges on the ability to tailor services to sponsor priorities-whether managing complex trial phases, navigating market access challenges or scaling novel therapy production.

Ultimately, industry participants that align strategic investments in technology, partnerships and ESG stewardship will be best positioned to capture emerging opportunities and mitigate systemic risks. The path forward is defined by agility, specialization and sustained innovation across the global outsourcing value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biotechnology & Pharmaceutical Services Outsourcing Market, by Service Type

  • 8.1. Clinical Trial Services
    • 8.1.1. Phase I
    • 8.1.2. Phase II
    • 8.1.3. Phase III
    • 8.1.4. Phase IV
  • 8.2. Consulting Services
    • 8.2.1. M&A Advisory
    • 8.2.2. Market Access & Reimbursement Consulting
    • 8.2.3. Portfolio Management
    • 8.2.4. Strategic Consulting
  • 8.3. Manufacturing Services
    • 8.3.1. API Production
    • 8.3.2. Contract Development & Manufacturing Organization (CDMO) Services
    • 8.3.3. Fill-Finish Services
    • 8.3.4. Formulation Development
    • 8.3.5. Packaging & Labeling
    • 8.3.6. Scale-Up & Tech Transfer
  • 8.4. Pharmacovigilance Services
  • 8.5. Preclinical Services
    • 8.5.1. Animal Studies
    • 8.5.2. Bioanalytical Testing
    • 8.5.3. DMPK Studies
    • 8.5.4. Pharmacology Studies
    • 8.5.5. Toxicology Testing
  • 8.6. Quality Management Services
  • 8.7. Regulatory Affairs Services
    • 8.7.1. Agency Communication & Representation
    • 8.7.2. Dossier Preparation
    • 8.7.3. Labeling & Packaging Compliance
    • 8.7.4. Pharmacovigilance & Safety Monitoring
    • 8.7.5. Regulatory Strategy & Submissions
  • 8.8. Research & Development Services
    • 8.8.1. Assay Development
    • 8.8.2. Biomarker Discovery
    • 8.8.3. Lead Identification & Optimization
    • 8.8.4. Target Validation

9. Biotechnology & Pharmaceutical Services Outsourcing Market, by Mode of Outsourcing

  • 9.1. Full-Service Outsourcing
  • 9.2. Functional Service Provider (FSP) Model
  • 9.3. Tactical/Project-Based Outsourcing

10. Biotechnology & Pharmaceutical Services Outsourcing Market, by Company Size

  • 10.1. Large Enterprises
  • 10.2. Small & Medium Enterprises (SMEs)

11. Biotechnology & Pharmaceutical Services Outsourcing Market, by Therapeutic Area

  • 11.1. Cardiovascular
  • 11.2. Dermatology
  • 11.3. Gastroenterology
  • 11.4. Immunology
  • 11.5. Infectious Diseases
  • 11.6. Metabolic Disorders
  • 11.7. Neurology
  • 11.8. Oncology
  • 11.9. Pediatrics
  • 11.10. Rare Diseases
  • 11.11. Respiratory

12. Biotechnology & Pharmaceutical Services Outsourcing Market, by Service Provider Type

  • 12.1. Consulting Firms
  • 12.2. Contract Development & Manufacturing Organizations (CDMOs)
  • 12.3. Contract Manufacturing Organizations (CMOs)
  • 12.4. Contract Research Organizations (CROs)
  • 12.5. Data Management & IT Service Providers
  • 12.6. Regulatory Affairs Firms

13. Biotechnology & Pharmaceutical Services Outsourcing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biotechnology & Pharmaceutical Services Outsourcing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biotechnology & Pharmaceutical Services Outsourcing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biotechnology & Pharmaceutical Services Outsourcing Market

17. China Biotechnology & Pharmaceutical Services Outsourcing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AmerisourceBergen Corporation
  • 18.6. Catalent, Inc.
  • 18.7. CEVA Logistics AG
  • 18.8. Charles River Laboratories, Inc.
  • 18.9. Concept Heidelberg GmbH
  • 18.10. Curia Global, Inc.
  • 18.11. Dalton Pharma Services by Seikagaku Corporation
  • 18.12. DHL International GmbH
  • 18.13. Eurofins Scientific (Ireland) Limited
  • 18.14. Evotec SE
  • 18.15. GenScript Biotech Corporation
  • 18.16. Icon PLC
  • 18.17. IQVIA HOLDINGS, INC.
  • 18.18. Laboratory Corporation of America Holdings
  • 18.19. Lachman Consultant Services, Inc.
  • 18.20. McKesson Corporation by Aurelius Group
  • 18.21. Medpace Holdings, Inc.
  • 18.22. Parexel International Corporation
  • 18.23. Syneos Health, Inc.
  • 18.24. Thermo Fisher Scientific Inc.
  • 18.25. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY M&A ADVISORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY M&A ADVISORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY M&A ADVISORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MARKET ACCESS & REIMBURSEMENT CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MARKET ACCESS & REIMBURSEMENT CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MARKET ACCESS & REIMBURSEMENT CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PORTFOLIO MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PORTFOLIO MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PORTFOLIO MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STRATEGIC CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STRATEGIC CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STRATEGIC CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY API PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY API PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY API PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION (CDMO) SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION (CDMO) SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION (CDMO) SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FILL-FINISH SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FILL-FINISH SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FILL-FINISH SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SCALE-UP & TECH TRANSFER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SCALE-UP & TECH TRANSFER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SCALE-UP & TECH TRANSFER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ANIMAL STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ANIMAL STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ANIMAL STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOANALYTICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOANALYTICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOANALYTICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DMPK STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DMPK STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DMPK STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOLOGY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOLOGY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOLOGY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TOXICOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TOXICOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY QUALITY MANAGEMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY QUALITY MANAGEMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY QUALITY MANAGEMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AGENCY COMMUNICATION & REPRESENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AGENCY COMMUNICATION & REPRESENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AGENCY COMMUNICATION & REPRESENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DOSSIER PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DOSSIER PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DOSSIER PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LABELING & PACKAGING COMPLIANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LABELING & PACKAGING COMPLIANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LABELING & PACKAGING COMPLIANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE & SAFETY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE & SAFETY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE & SAFETY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY & SUBMISSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY & SUBMISSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY & SUBMISSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FULL-SERVICE OUTSOURCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FULL-SERVICE OUTSOURCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FULL-SERVICE OUTSOURCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TACTICAL/PROJECT-BASED OUTSOURCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TACTICAL/PROJECT-BASED OUTSOURCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TACTICAL/PROJECT-BASED OUTSOURCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SMALL & MEDIUM ENTERPRISES (SMES), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SMALL & MEDIUM ENTERPRISES (SMES), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SMALL & MEDIUM ENTERPRISES (SMES), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS (CMOS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS (CMOS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS (CMOS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT & IT SERVICE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT & IT SERVICE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT & IT SERVICE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROP